| Literature DB >> 29026725 |
Tae Ho Kim1, Jae Seung Chang1, In Deok Kong1.
Abstract
BACKGROUND: Exercise has been identified as a beneficial intervention to enhance quality of life in breast cancer survivors. In addition, there has been a noteworthy increase in studies emphasizing the benefits of exercise in cancer. We sought to summarize the empirical literature concerning the effects of exercise on physical fitness and biomarker levels in breast cancer survivors according to the type of exercise.Entities:
Keywords: Biomarkers; Breast cancer survivors; Physical fitness; Types of exercise
Year: 2017 PMID: 29026725 PMCID: PMC5618735 DOI: 10.15280/jlm.2017.7.2.55
Source DB: PubMed Journal: J Lifestyle Med ISSN: 2234-8549
Effects of exercise on physical fitness
| Reference | Cancer stage | Participants | Mode | Intervention | Outcome |
|---|---|---|---|---|---|
| Pinto et al. [ | Stage I–II | 3 yrs after treatment. | AE | 2 × / wk for 12 wks at 55–65% maximum intensity. | ↑Δ1-mile walking test |
| 12 control | ↓Δ%body fat | ||||
| 12 exercise | |||||
| Ohira et al. [ | Stage I–III | Completing treatment. | RE | 2 × / wk for 24 wks. | ↑ΔBench press |
| 43 control | |||||
| 43 exercise | |||||
| Helen et al. [ | Stage I–IIIa | 58 mo. after treatment. | Comb | 3 × / wk for 12 wks. | ↑ΔLeg press |
| Pre– and post-intervention | AE: 20 min, cycling and rowing. | ||||
| RE: Whole-body progressive, 10–15 reps, two sets. | |||||
| Irwin et al. [ | Stage I–IIIa | 6 mo. after treatment. | AE | 3 × / wk for 24 wks at 50–80% maximum intensity. | ↓Δ%body fat |
| 33 control | |||||
| 36 exercise | |||||
| Antonia et al. [ | N/A | 2 yrs after treatment. | AE | Dance exercise. | ↓ΔHand grip strength |
| 13 control | 3 × / wk for 24 wks at 65–80% maximum intensity. | ||||
| 14 exercise | |||||
| Waltman et al. [ | Stage I–V | 6 mo. after treatment. | RE | 2 × / wk for 24 mo. | ↑ΔHip extension |
| 125 control | 8–12 reps, two sets. | ↑ΔHip flexion | |||
| 123 exercise | ↑ΔKnee extension | ||||
| ↑ΔKnee flexion | |||||
| Winters et al. [ | Stage I–IIIa | 1 yr after treatment. | RE | 1 × / wk for 12 mo. 8–12 reps, three sets. | ↑ΔBench press |
| 54 control | ↑ΔLeg press | ||||
| 52 exercise | |||||
| Laura et al. [ | Stage I–IIIa | 2 mo. after treatment. | Comb | 2 × / wk for 3 mo. | ↑ΔPredicted VO2max |
| 13 control | AE: Moderate, 150 min/week. | ↑ΔBack / leg strength | |||
| 15 exercise | RE: Whole-body band exercise, 20 reps. | ||||
| Benton et al. [ | Stage I–III | Completing treatment. | RE | 2 × / wk for 8 wks. | ↑ΔChest press |
| 20 pre– and post-intervention | 10–12 reps, three sets. | ||||
| Hannah et al. [ | Stage I–III | 6 mo. after treatment. | Comb | 2 × / wk for 12 mo. | ↑ΔVO2max |
| 38 control | AE: 60–80% maximum intensity. | ||||
| 45 exercise | RE: Whole-body progressive, 9–12 reps, three sets. | ||||
| Lianne et al. [ | Stage I–IIIa | Completing treatment. | AE | 6 wks at 55–80% maximum intensity. | ↑ΔVO2max |
| 10 control | |||||
| 23 exercise | |||||
| Michael et al. [ | N/A | 17 mo. after treatment. | Comb | 3 × / wk for 12 wks. | ↑ΔTimed up and go |
| 52 pre– and post-intervention | AE: 70–85% maximum intensity. | ↑ΔLeg press | |||
| RE: Whole-body progressive, 8–12 reps, two sets. | ↑ΔChest press | ||||
| ↑ΔBack scratch | |||||
| ↑ΔSingle-leg stand |
Notes:↑Increase,↓Decrease.
AE: aerobic exercise, Comb: combined exercise, RE: resistance exercise, reps: repetitions, VO2max: maximal oxygen consumption.
Effects of exercise on mediators of inflammation
| Reference | Cancer stage | Participants | Mode | Intervention | Outcome |
|---|---|---|---|---|---|
| Martina et al. [ | Stage I–IIIa | Completing treatment. | RE | 2 × / wk for 12 wks. | ↓ΔIL-6 |
| 49 control | 8–12 reps, three sets. | ||||
| 54 exercise | |||||
| Amanda et al. [ | Stage I–IIIa | 17 wks after treatment. | RE | 3 × / wk for 16 wks. | ≒ΔTNF-α |
| 19 control | 8–10 reps, three sets. | ≒ΔIL-6 | |||
| 20 exercise | ≒ΔIL-10 | ||||
| ≒Δhs-CRP | |||||
| ↓ΔTNF-α | |||||
| Nigel et al. [ | Stage I–IIIc | 12 mo. after treatment. | RE | 15–20 reps, three sets. | ≒ΔIL-6 |
| 22 control | 24 hours. | ≒ΔTNF-α | |||
| 20 exercise | ≒Δhs-CRP | ||||
| Swisher et al. [ | Stage I–III | 3 mo. after treatment. | AE | 2 × / wk for 12 wks at 60–75% maximum intensity. | ≒Δhs-CRP |
| 10 control | ≒ΔIL-6 | ||||
| 13 exercise | ≒ΔTNF-α | ||||
| ≒ΔAdiponectin | |||||
| ≒ΔInsulin | |||||
| ≒ΔLeptin | |||||
| Lianne et al. [ | Stage I–IIIa | Completing treatment. | AE | 6 wks at 55–80% maximum intensity. | ≒ΔInsulin |
| 10 control | ≒ΔGlucose | ||||
| 23 exercise | ≒ΔHOMA-IR | ||||
| ≒Δhs-CRP | |||||
| Giallauria et al. [ | Stage I | N/A | AE | 3 × / wk for 12 wks at 70% maximum intensity. | ↓ΔHMGB-1 |
| 33 control | |||||
| 62 exercise | |||||
| Laura et al. [ | Stage I–II | 4 wks after treatment. | Comb | 2 × / wk for 3 mo. | ≒ΔIL-6 |
| 22 control | AE: 48–52 heart reserve. | ≒ΔIL-8 | |||
| 20 exercise | RE: Whole-body band exercise, 15 reps, two sets. | ↓ΔIL-10 | |||
| ≒ΔTNF-α | |||||
| Scott et al. [ | Stage I–III | 18 mo. after treatment. | Comb | 3 × / wk for 3 mo. | ↓ΔLeptin |
| 38 control | AE: 65–85% maximum intensity. | ↓ΔTotal cholesterol | |||
| 42 exercise | RE: Whole-body band exercise 10–15 min. | ||||
| Tish et al. [ | N/A | 3 yrs after treatment. | Comb | 3 × / wk for 12 mo. | ≒ΔOsteocalcin |
| 78 control | AE: 65–70% maximal heart rate. | ≒ΔVitamin D | |||
| 76 exercise | RE: Whole-body progressive, 8 reps, one set. | ||||
| Gomez et al. [ | Stage I–II | 18 mo. after treatment. | Comb | 3 × / wk for 8 wks | ↓ΔCTACK |
| 8 control | AE: 70–80% maximal heart rate. | ||||
| 8 exercise | RE: Whole-body progressive, 12–15 reps, three sets. | ||||
| Adrian et al. [ | Stage I–IIIb | Completing treatment. | AE | 2 × / wk for 15 wks at 70–75% maximum intensity. | ≒ΔIL-1 |
| 28 control | ≒ΔIL-4 | ||||
| 25 exercise | ≒ΔIL-6 | ||||
| ≒ΔIL-10 | |||||
| ≒ΔTNF-α | |||||
| Sara et al. [ | Stage I–IIIa | 12 mo. after treatment. | Comb | 3 × wk for 6 mo. | ≒ΔIL-6 |
| 37 intervention | AE: 60–80% maximum intensity. | ≒Δhs-CRP | |||
| 38 control | RE: Whole-body yoga exercise, 30 min. | ≒ΔTNF-α | |||
| Nora et al. [ | Stage I–III | 12 mo. after treatment. | Comb | 2 × / wk | ↓ΔC-peptide |
| 19 pre– and post-intervention | AE: walking 3–3.5 mph 30 min. | ||||
| RE: Whole-body progressive, 8–12 reps, two sets. | |||||
| Guinan et al. [ | Stage I–III | 2 mo. after treatment. | AE | 2 × / wk for 8 wks at 45–65% maximum intensity. | ≒ΔInsulin |
| 10 control | ≒ΔHbA1c | ||||
| 16 exercise | |||||
| Campbell et al. [ | Stage I–IIIa | 3 mo. after treatment. | AE | 2 × / wk for 24 wks at 60% maximum intensity. | ↓ΔHDL-c |
| 14 pre– and post-intervention | |||||
| Emily et al. [ | Stage I–III | 5 yrs after treatment. | RE | 2 × / wk for 6 mo. | ≒Δhs-CRP |
| 12 pre– and post-intervention | 8–12 reps, two sets. | ||||
| Befort et al. [ | Stage I–IIIc | 3 mo. after treatment. | AE | 225 min / wk for 12 wks. | ↓ΔInsulin |
| 36 pre– and post-intervention | Moderate walking, 225 min per week. | ↓ΔLeptin | |||
| Kerri et al. [ | Stage I–IIIa | 1 yr after treatment. | RE | 12 mo. | ↑ΔOsteocalcin |
| 54 control | 8–12 reps, three sets. | ||||
| 52 exercise | |||||
| Waltman et al. [ | Stage I–II | 6 mo. after treatment. | RE | 2 × / wk for 24 mo. | ↓ΔAlkphase B |
| 113 control | 8–12 reps, two sets. | ↓ΔNTx | |||
| 110 exercise | |||||
| Irwin et al. [ | Stage I–IIIa | 6 mo. after treatment. | AE | 3 × / wk for 24 wks at 50–80% maximum intensity. | ↓ΔInsulin |
| 33 control | ↓ΔIGF-1 | ||||
| 36 exercise | ↓ΔIGFBP-3 | ||||
| Ligibel et al. [ | Stage I–III | After 3 mo. treatment. | Comb | 16 wks. | ↓ΔInsulin |
| 42 intervention | RE: whole-body exercise, 50 min per week. | ||||
| 40 control | AE: 90 min per week. |
Notes:↑Increase,↓Decrease, ≒ No change.
AE: aerobic exercise, Comb: combined exercise, RE: resistance exercise, reps: repetitions, VO2max: maximal oxygen consumption. IL-1: interleukin-1, IL-4: interleukin 4, IL-6: interleukin-6, IL-8: interleukin-8, IL-10: interleukin-10, TNF-α: tumor necrosis factor-α, CTACK: cutaneous T-cell-attracting chemokine, hs-CRP: high sensitivity C-reactive protein, HbA1c: hemoglobin A1c, HDL-c: high-density lipoprotein cholesterol, HOMA-IR: homeostatic model assessment of β-cell function and insulin resistance, HMGB-1: high-mobility group box-1, Alkphase-B: bone-specific alkaline phosphatase, NTx: N-telopeptides of type 1 collagen, IGF-1: insulin-like growth factor gene-1, IGFBP-3: insulin-like growth factor-binding protein-3.